FilingReader Intelligence
Boya Bio bolsters operations with profit distribution, scope expansion
March 18, 2025 at 06:18 PM UTC•By FilingReader AI
Boya Bio-Pharmaceutical Group (SZSE:300294) announced a comprehensive strategy for growth in 2025, balancing shareholder value with operational expansion. The company proposes a cash dividend of RMB 1.60 per 10 shares, totaling RMB 80.68 million, drawing from a net profit of RMB 396.99 million. This distribution represents 40.65% of net profit attributable to shareholders.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
The company's 2024 annual financial reportMarch 18, 2025 at 12:14 PM UTC
2024 Annual Financial ReportMarch 18, 2025 at 12:14 PM UTC
2024 Annual ReportMarch 18, 2025 at 12:14 PM UTC
2024 Annual Audit ReportMarch 18, 2025 at 12:14 PM UTC
2024 Annual Report of the Board of DirectorsMarch 18, 2025 at 12:14 PM UTC
The company's announcement on the profit distribution plan for 2024March 18, 2025 at 12:14 PM UTC
The company's announcement on the provision of asset impairment in 2024March 18, 2025 at 12:14 PM UTC
Announcement of the Company on Expanding the Company's Business Scope and Amending the Articles of AssociationMarch 18, 2025 at 12:14 PM UTC
News Alerts
Get instant email alerts when Boya Bio-Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime